Biotage AB launches share buy-back

The board of directors of Biotage AB (publ) has resolved to start a share buy
-back program in accordance with the Annual General Meeting’s resolution to
authorize the board to decide on the acquisition and sale of the company’s own
shares.
At the Annual General Meeting held on 28 April 2015, the board was authorized to
decide on the acquisition and sale of the company’s own shares up and until the
forthcoming Annual General Meeting. The shares acquired may not exceed 10 per
cent of the total number of outstanding Biotage shares at any time. The purpose
of the repurchase program is to give the board a wider freedom of action in the
work with the company’s capital structure and thereby improve shareholder value.
Acquisition and sale of shares will take place on the NASDAQ OMX Stockholm at a
price within the price interval at any time recorded. Biotage currently does not
own any own shares.

Kontaktperson:
Torben Jörgensen, VD och koncernchef
Tel: 0707-49 05 84, torben.jorgensen@biotage.com


Biotage discloses the information provided herein pursuant to the Swedish
Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The
information was submitted for publication at 08.30 on 29 April 2015.



About Biotage
Biotage offers efficient separation technologies from analysis to industrial
scale and high quality solutions for analytical chemistry from research to
commercial analysis laboratories. Biotage’s products are used by government
authorities, academic institutions, pharmaceutical and food companies, among
others. The company is headquartered in Uppsala and has offices in the US, UK,
China and Japan. Biotage has approx. 290 employees and had sales of 490 MSEK in
2014. Biotage is listed on the NASDAQ OMX Stockholm stock exchange. Website:
www.biotage.com